content top

RSNA/ESR: Essentials in Oncologic Imaging: What Radiologists Need to Know: Part II.

Time:

2:00 PM – 5:45 PM

Code: SR42

Objective:

This session provides a practical, clinically-relevant summary of key imaging issues in common cancers using an interactive, case-based approach. It also provides an overview of current cancer-related terminology, definitions and ‘buzz’ words used in everyday practice. Attendees will learn how imaging can optimally assess and measure tumor treatment response, providing a value-added radiology report.

This session includes eight sections, the first is : Terminology, Definitions, and Buzzwords, which provides an overview and precise explanation of current cancer-related terminology, definitions and ‘buzz’ words used in everyday practice. Attendees will understand why and how this terminology should ensure and simplify communication with all specialists involved in cancer management, including clinicians, researchers as well as other radiologists. Attendees will also learn common tricks and traps in providing a radiology report, illustrated with clinical cases. The second section, Liver Cancers (Primary, Metastases), provides an overview of the AASLD/EASL imaging criteria for noninvasive diagnosis of hepato-cellular carcinoma. It also provides best practice CT/MR/US Imaging techniques that optimize characterization, detection and staging of primary and metastatic liver tumors. Attendees will understand the key role specific findings reported by radiologists have in determining patient treatment options for hepato-cellular carcinoma. The third section is Prostate Cancer, in which attendees will learn the key clinical indications for in prostate cancer. This section provides an overview of essential MR Imaging techniques in detection, characterization, localization and staging of prostate cancer. Attendees will understand how MR Imaging influences therapeutic decisions and how best to provide a value added MR report. The fourth section is a question and answer session.

The fifth one is Lymphoma, which provides a practical, clinically relevant summary of key imaging issues in Hodgkin and non-Hodgkin lymphoma. Attendees will learn how imaging, especially PET and PET-CT scans can optimally assess and measure tumor treatment response, providing a value-added radiology report. The sixth section is Musculoskeletal Neoplasms, which reviews imaging features of common malignant musculoskeletal neoplasms. This section will illustrate key imaging findings required for staging of bone and soft tissue tumors, as well as associated imaging pitfalls. The section describes criteria for conventional imaging, perfusion MR Imaging and diffusion-weighted MR Imaging and PET/CT in assessing response to treatment in musculoskeletal neoplasms. The seventh section, Chemo and Radiation Therapy-induced Toxicity, provides an overview of organ-specific toxicity and other adverse effects of chemo- and radiotherapy. It also reviews the key imaging findings of therapy-induced organ toxicity and adverse effects. Attendees will understand how to differentiate inflammatory, infectious, fibrotic, and necrotic changes from tumor recurrence. The eighth section is another question and answer session.

 

Share


Leave a Reply

*